The present invention relates to compounds of formula (I): ##STR00001## including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

A condensed cyclic compound and an organic light-emitting device including the same. The a condensed cyclic compound represented by Formula 1:

##STR00001##

A condensed cyclic compound and an organic light-emitting device including the same. The a condensed cyclic compound represented by Formula 1:

##STR00001##

The present invention relates to compounds of formula (I):

##STR00001##

including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The present invention relates to compounds of formula (I):

##STR00001##

including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of, for example, cancer.

The present disclosure relates to a novel compound, and an organic electroluminescent device including the same, and by using the compound according to the present disclosure in an organic material layer, preferably a light emitting layer or an auxiliary light emitting layer, of an organic electroluminescent device, light emission efficiency, a driving voltage, a lifetime and the like of the organic electroluminescent device may be enhanced.

Provided are a condensed cyclic compound having the following structure:

##STR00001##

wherein ring D.sub.1 and ring D.sub.2 are each independently a C.sub.6-C.sub.20 aromatic ring, and an organic light-emitting device including the same.

Provided are a condensed cyclic compound having the following structure:

##STR00001##

wherein ring D.sub.1 and ring D.sub.2 are each independently a C.sub.6-C.sub.20 aromatic ring, and an organic light-emitting device including the same.

Proposed is a novel quinizarin derivative, and the novel quinizarin derivative has the abilities to inhibit a BET protein, and thus can be used as a pharmaceutical composition for the prevention or treatment of BET protein-related diseases, such as cancer, autoimmune or inflammatory diseases, metabolic diseases, and viral diseases. Particularly, the novel quinizarin derivative has the abilities to inhibit lipogenesis and the expression of liposynthetic factors, and thus can be used as a pharmaceutical composition for the treatment of non-alcoholic fatty liver.

Proposed is a novel quinizarin derivative, and the novel quinizarin derivative has the abilities to inhibit a BET protein, and thus can be used as a pharmaceutical composition for the prevention or treatment of BET protein-related diseases, such as cancer, autoimmune or inflammatory diseases, metabolic diseases, and viral diseases. Particularly, the novel quinizarin derivative has the abilities to inhibit lipogenesis and the expression of liposynthetic factors, and thus can be used as a pharmaceutical composition for the treatment of non-alcoholic fatty liver.